NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
Rhea-AI Summary
NanoViricides (NYSE American: NNVC) closed a registered direct offering to a single institutional investor, raising aggregate gross proceeds of approximately $2,000,001.
The securities were priced at-the-market at $1.50 per share with accompanying warrants exercisable at $1.75 per share after six months, expiring in three years.
AI-generated analysis. Not financial advice.
Positive
- Raised approximately $2,000,001 in gross proceeds through the registered direct offering
- Warrants with $1.75 exercise price could provide additional capital if exercised
- Offering completed at at-the-market pricing to an institutional investor
Negative
- New shares and warrants create immediate and potential future shareholder dilution
- Exercise of three-year warrants could further expand share count over time
News Market Reaction – NNVC
On the day this news was published, NNVC declined 3.64%, reflecting a moderate negative market reaction. Argus tracked a peak move of +21.4% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $32.69M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NNVC gained 2.03% with heavy volume while momentum peers showed mixed moves, with a median change around -4.4% according to the sector scanner, indicating both company-specific financing news and broader biotech volatility.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 15 | Registered offering pricing | Negative | -14.9% | Priced ~$2M registered direct unit offering with 3-year warrants. |
Prior offering news on May 15, 2026 led to a sharp -14.94% drop, highlighting sensitivity to equity financings.
This announcement closes the registered direct offering first detailed on May 15, 2026, when NanoViricides priced a deal expected to raise about $2 million and the stock fell 14.94%. That financing followed a series of capital raises and ongoing going‑concern language in recent SEC filings. Today’s closing confirms the same structure (common or pre‑funded units plus warrants), extending a pattern where equity issuance has been a key funding tool for advancing NV‑387 toward Phase II trials.
Historical Comparison
In the past 6 months, NNVC had 1 prior offering headline, which saw a -14.94% move. Today’s closing of the same financing contrasts with the earlier sharp selloff.
The current closing follows the earlier pricing announcement for this registered direct unit financing, completing the same offering structure.
Regulatory & Risk Context
An effective Form S-3 from December 15, 2025 registers up to 7,142,858 resale shares tied to Series A and B warrants. If fully exercised for cash, those warrants could deliver about $13.4 million in gross proceeds to the company, though resale proceeds go to the selling stockholder.
Market Pulse Summary
This announcement confirms closing of a registered direct offering for $2,000,001 in gross proceeds, issuing 1,333,334 shares or pre‑funded warrants plus an equal number of three‑year warrants at $1.75. It draws on an effective Form S-3 shelf, alongside other recent financings disclosed in 424B5 and 10‑Q filings that note going‑concern risks. Investors may watch future use of shelf capacity, warrant exercises, and additional offerings as key signals for funding strategy.
Key Terms
registered direct offering financial
pre-funded warrants financial
warrants financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,333,334 million shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares (the "Offering"). The Offering was made to a single, fundamental institutional investor and priced at-the-market price of US
D. Boral Capital LLC acted as the exclusive placement agent for the Offering.
The ordinary shares (or pre-funded warrants in lieu thereof) were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333- 271706), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on May 22, 2023.
A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC and is available on the SEC's website at https://www.sec.gov/. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NanoViricides
NanoViricides, Inc., is a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape. Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD). This could provide 7 years market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is a revolutionary antiviral that we believe will be the drug offered at "first visit" when the patient presents to a doctor with any respiratory viral illness. NV-387 was also found to be highly effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends, and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. These risks include, but are not limited to, the ability to complete the offering on the terms described or at all, the ability to satisfy customary closing conditions, market conditions, regulatory developments affecting the digital asset and stablecoin industries, and other risks described in the Company's filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading "Risk Factors" in the Company's Annual Reports on Form 20-F, as may be supplemented or amended by the Company's Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information, or otherwise.
Contacts
For Inquiries, Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
Source: NanoViricides, Inc.
View the original press release on ACCESS Newswire